Zealand Pharma Completes Week 38 Share Buy-Back Activities
News related to:Zealand Pharma · 2 min read
COPENHAGEN, Denmark, Zealand Pharma, a biotechnology company focused on advancing medicines for obesity and metabolic health, reported on September 21, 2026, its share buy-back activities for the week of September 14 to September 18, 2026. The company is executing a share buy-back program in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (the Safe Harbour Regulation).
The program, which commenced on May 7, 2026, allows Zealand Pharma to repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that can be acquired under the program is 7,152,557, and the program is set to conclude no later than October 31, 2026. Danske Bank has been appointed as the lead manager for the program, making its own trading decisions independently of the company.
During the week of September 14 to September 18, 2026, Zealand Pharma executed transactions under the program. As a result of these transactions, the company now holds a total of 4,495,842 treasury shares, which correspond to approximately 6.28% of the company’s share capital. The total number of shares in Zealand Pharma is 71,610,005, each with a nominal value of DKK 1.
The company’s share buy-back program is part of its ongoing efforts to optimize its capital structure and enhance shareholder value. Zealand Pharma, founded in 1998, is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. The company is dedicated to transforming the future of metabolic health through its innovative drug development efforts. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, with two products already on the market and three candidates in late-stage development. The company collaborates with global pharmaceutical and biotechnology partners for research, development, and commercialization.
The company’s commitment to its shareholders and the broader biotechnology sector is evident in its ongoing efforts to optimize its capital structure and enhance shareholder value through strategic initiatives like the share buy-back program. Zealand Pharma’s focus on advancing medicines for obesity and metabolic health underscores its dedication to improving patient outcomes and driving innovation in the field.